Canada Takes The Lead In Bringing Injectable Truvada Replacement Drug to Market

An injectable form of AIDS drug could be available in the US very soon to replace the current antiretroviral (ARV) regimen that includes taking Truvada daily.


Truvada Bone Lawsuit News

Thursday, September 24, 2020 - Forgetting to take the daily dose of Truvada is a problem that prevents physicians from taking a more active role in helping their HIV positive patients manage their AIDS symptoms. Truvada can help AIDS patients more effectively manage their disease, but must be taken daily if it is to build up in the blood and be effective. Truvada does not cure AIDS but is effective when used in combination with other drugs to lower the AIDS patient's viral load and stop the disease from progressing. Forgetting to take Truvada for a day or two, however. could cause the virus to worsen into a life-threatening condition. Truvada patients have also reported extreme side effects from taking the drug such as bone breakage and kidney failure. Still, others report experiencing life-threatening ketoacidosis or the build us of acidic blood. Many Truvada patients have hired Truvada bone breakage and kidney failure lawyers and sued Gilead Sciences, the maker of the drug, for failing to warn them of Truvada's dangerous bone breakage and kidney failure side effects. Plaintiffs seek reimbursement of medical expenses, lost wages, and other damages. Truvada patients that fear starting on the drug now have hope that a breakthrough in the form of a new injectable drug will help them to manage their disease more easily and safely. Truvada lawyers offer a free no obligation consultation before filing a lawsuit claim against the makers of Truvada, Gilead Sciences, Inc.

HIV positive Canadians can now replace their daily dose of Truvada or other retroviral drugs with 12 easy, monthly injections. Newswire Canada reports that Dacia Hibbert, General Manager of ViiV Healthcare Canada, announced: "We are proud to make Cabenuva and Vocabria available to people living with HIV. Cabenuva will give people living with HIV the option of maintaining viral suppression with 12 treatments per year." Newswire explained, "Cabenuva is the first and only once-monthly, complete long-acting injectable regimen indicated for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and suppressed."

Health officials in the United States welcomed the Canadian announcement and hoped a similar one in the US could be forthcoming. Janssen Pharmaceuticals recently announced that they were hopeful the injectable AIDS drug would be available in the US very soon. The company announced the results of Phase 3 of a study that demonstrates the safety of long-acting injectable HIV treatment using a regimen of Rilpivirine And Cabotegravir through 96 Weeks. Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health, Janssen Research & Development LLC. "We are excited that this long-acting injectable regimen could potentially provide a paradigm shift in managing the experience of living with HIV from daily to monthly dosing," according to Drugs.com.

Researchers and experts testing the new injectable drug are excited to offer patients a way to reduce their AIDS management drug dosing schedules from 365 times per year down to 12. Experts think the ease of only having to remember a monthly appointment will cause doctors to play a more active role in executing AIDS tests and recommending the treatment.

More Recent Truvada Bone Lawsuit News:

No-Cost, No-Obligation Truvada Lawsuit Case Review If You or a Loved One Suffered from Truvada Bone or Kidney Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.